| dc.rights.license | CC-BY-NC-ND | |
| dc.contributor.advisor | Mantel-Teeuwisse, A.K. | |
| dc.contributor.author | Brinkhuis, Francine | |
| dc.date.accessioned | 2023-06-30T23:00:56Z | |
| dc.date.available | 2023-06-30T23:00:56Z | |
| dc.date.issued | 2023 | |
| dc.identifier.uri | https://studenttheses.uu.nl/handle/20.500.12932/44064 | |
| dc.description.sponsorship | Utrecht University | |
| dc.language.iso | EN | |
| dc.subject | In this report, the trend in added benefit of novel oncology drugs was explored over time. All oncology drugs authorized by the EMA between 1995-2020 were considered. We focused on added benefit ratings of Health Technology Assessment (HTA) agencies of Europe and the US, as well as oncological frameworks and a French organization that publishes medical evaluations. Furthermore, we assessed the trend in drug revenues over time, as well as the association between added benefit and revenues. | |
| dc.title | Clinical Benefit and Drug Revenues: a Retrospective Study of Oncology Drugs Approved Between 1995 and 2020 | |
| dc.type.content | Master Thesis | |
| dc.rights.accessrights | Open Access | |
| dc.subject.keywords | added therapeutic benefit; cost-effectiveness assessment; clinical evidence; health technology
assessment; regulation; reimbursement; relative-effectiveness assessment; drug revenues; oncology; orphan drugs; conditional market authorization; approvals under exceptional circumstances; | |
| dc.subject.courseuu | Drug Innovation | |
| dc.thesis.id | 2152 | |
